Enovis Corp
NYSE:ENOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.8), the stock would be worth $22.04 (2% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.9 | $22.49 |
0%
|
| 3-Year Average | 0.8 | $22.04 |
-2%
|
| 5-Year Average | 0.8 | $22.05 |
-2%
|
| Industry Average | 3.1 | $81.31 |
+262%
|
| Country Average | 2.5 | $65.47 |
+191%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Enovis Corp
NYSE:ENOV
|
1.3B USD | 0.9 | -1.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 9 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 3 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 5.4 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 2.1 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 3.5 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 4.6 | 43 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 27.5 | 41.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 2.1 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 1.6 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 4.9 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Enovis Corp
Glance View
Enovis Corp., a company with a steadfast commitment to innovation and growth, operates within the specialized world of medical technology. Originally a part of Colfax Corporation, it underwent a strategic transformation, branching out into its own entity, laser-focused on advancing human mobility through cutting-edge orthopedic solutions. Enovis has carved its niche by developing and manufacturing high-quality, bespoke orthopedic products that serve both surgical and non-surgical needs. These offerings are designed to enhance patient recovery and mobility, thereby improving quality of life. Its extensive product portfolio includes surgical implants, bracing, rehabilitation solutions, and intelligent digital care platforms, positioning Enovis at the intersection of healthcare and technology. Revenue for Enovis streams from its diverse array of products and solutions targeted at healthcare professionals and institutions worldwide. The company thrives by engaging in both direct sales and a network of distributors to ensure its innovative solutions reach a broad spectrum of the healthcare landscape. By continually investing in research and development, Enovis maintains its competitive edge, launching new products that address evolving medical needs. This proactive approach not only caters to the existing demand but also stimulates new markets by educating and training medical professionals and leading them through transformative, evidence-based clinical outcomes. In essence, Enovis Corp. excels by integrating science and technology to fuel both financial growth and human betterment.